McArthur, G., Larkin, J., Dréno, B., Ascierto, P., Liszkay, G., Maio, M., Mandal´, M., Demidov, L., Stroyakovskiy, D., Thomas, L., De la Cruz-Merino, L., Atkinson, V., Dutriaux, C., Garbe, C., Wongchenko, M., Hsu, J., Koralek, D., Rooney, I., Yan, Y., & Ribas, A. (n.d.). 25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study. European journal of cancer, 51, S722–S723. http://access.bl.uk/ark:/81055/vdc_100030687872.0x000040